Assenagon Asset Management S.A. Acquires 65,074 Shares of DaVita Inc. $DVA

Assenagon Asset Management S.A. lifted its stake in DaVita Inc. (NYSE:DVA) by 1,951.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 68,408 shares of the company’s stock after purchasing an additional 65,074 shares during the period. Assenagon Asset Management S.A. owned about 0.10% of DaVita worth $9,089,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. HighTower Advisors LLC boosted its position in DaVita by 1.8% in the 1st quarter. HighTower Advisors LLC now owns 16,333 shares of the company’s stock valued at $2,498,000 after buying an additional 296 shares during the period. American Century Companies Inc. raised its stake in shares of DaVita by 34.6% during the first quarter. American Century Companies Inc. now owns 84,513 shares of the company’s stock valued at $12,928,000 after acquiring an additional 21,710 shares in the last quarter. Raymond James Financial Inc. boosted its holdings in shares of DaVita by 6.8% in the first quarter. Raymond James Financial Inc. now owns 27,604 shares of the company’s stock valued at $4,223,000 after purchasing an additional 1,768 shares during the period. Northern Trust Corp grew its stake in DaVita by 20.2% in the first quarter. Northern Trust Corp now owns 890,632 shares of the company’s stock worth $136,240,000 after purchasing an additional 149,858 shares in the last quarter. Finally, Wellington Management Group LLP increased its holdings in DaVita by 207.9% during the 1st quarter. Wellington Management Group LLP now owns 8,348 shares of the company’s stock worth $1,277,000 after purchasing an additional 5,637 shares during the period. Institutional investors own 90.12% of the company’s stock.

DaVita Stock Performance

NYSE:DVA opened at $115.18 on Friday. The company’s 50-day simple moving average is $121.38 and its 200-day simple moving average is $131.45. DaVita Inc. has a fifty-two week low of $113.97 and a fifty-two week high of $179.60. The stock has a market capitalization of $8.13 billion, a P/E ratio of 11.86, a P/E/G ratio of 0.87 and a beta of 1.00.

DaVita (NYSE:DVA) last posted its earnings results on Wednesday, October 29th. The company reported $2.51 EPS for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.66). DaVita had a net margin of 5.80% and a negative return on equity of 13,370.89%. The firm had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.43 billion. During the same period in the previous year, the company earned $2.59 EPS. The company’s revenue was up 4.8% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. On average, research analysts forecast that DaVita Inc. will post 10.76 EPS for the current year.

Analysts Set New Price Targets

DVA has been the topic of a number of recent research reports. Cowen reissued a “hold” rating on shares of DaVita in a research report on Monday, November 3rd. Bank of America dropped their target price on shares of DaVita from $145.00 to $140.00 and set an “underperform” rating on the stock in a report on Wednesday, September 10th. Weiss Ratings restated a “hold (c)” rating on shares of DaVita in a report on Monday, December 15th. Barclays lowered their price target on shares of DaVita from $149.00 to $143.00 and set an “equal weight” rating for the company in a research report on Thursday, October 30th. Finally, Zacks Research raised shares of DaVita from a “strong sell” rating to a “hold” rating in a report on Friday, November 28th. One equities research analyst has rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, DaVita currently has an average rating of “Hold” and a consensus target price of $148.00.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.